Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

110

Participants

Timeline

Start Date

August 26, 2025

Primary Completion Date

August 25, 2028

Study Completion Date

February 25, 2029

Conditions

Metastatic Solid TumorOvarian CancerBreast CancerBRCA 1 /2 and / or HRDAdvanced Solid Tumors

Interventions

DRUG

SYN818 and Olaparib will be administered

Patients will orally receive SYN818 and Olaparib

Trial Locations (2)

RECRUITING

FuDan University Shanghai Cancer Center, Shanghai

RECRUITING

FuDan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd

INDUSTRY

NCT07156253 - Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter